The IHME-led Global Burden of Disease analysis published in The Lancet represents a large-scale observational modeling study drawing on 204 countries and territories from 1990-2023, not an RCT, with inherent uncertainties in prevalence estimates due to data gaps in low-resource settings and reliance on covariates rather than direct measurement. While the source correctly flags the rise to 1.2 billion cases and the post-2019 acceleration in anxiety (47%) and MDD (24%), it underplays how diagnostic expansion, reduced stigma, and improved surveillance inflate counts alongside genuine incidence shifts. This doubling tracks with parallel rises documented in WHO's 2022 World Mental Health Report and a 2023 JAMA Psychiatry meta-analysis of 100+ studies showing pandemic-era spikes tied to economic disruption rather than solely viral effects. Critically, coverage misses the gender and adolescent peaks as signals of entrenched inequalities: women face compounded risks from unpaid care burdens and violence exposure, per longitudinal data in The Lancet Psychiatry, while 15-19 year olds navigate social media amplification of isolation amid declining community ties. Conflicts of interest are minimal here as IHME maintains independence via Gates Foundation funding, yet broader field critiques note pharma influence on disorder classifications. True drivers—poverty, housing insecurity, and eroded social capital—demand prevention frameworks over treatment silos, a gap the original reporting leaves unaddressed.